drugset / Trial / NCT04513639
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Phase 2/3
Recruiting
176 enrolled
Oslo University Hospital
Alesund Hospital · collabFørde Central Hospital · collabHaukeland University Hospital · collabHelse Nord-Trøndelag HF · collabHelse Stavanger HF · collabNordlandssykehuset HF · collabSorlandet Hospital HF · collabSt. Olavs Hospital · collabSykehuset Ostfold · collabThe Hospital of Vestfold · collabUniversity Hospital of North Norway · collabUniversity Hospital, Akershus · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first line treatment at progressive disease. To establish a homogenous group of MRD negative patients after first line treatment including autologous stem cell transplantation, patients are enrolled at diagnosis and treated with Norwegian standard of care first line treatment. MRD negative patients will move on to the randomized part.
Timeline
- Start
- 2020-08-27
- Primary completion
- 2031-06-01
- Completion
- 2032-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | — | — |
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | Dexamethasone | Small molecule | — | — |